CompletedNot Applicable

Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis

United States24 participantsStarted 2022-02-15

Plain-language summary

Getting enough sleep is important for maximizing health and well-being. When it comes to health, sleep is as vital as regular exercise and eating a balanced diet. Not getting enough sleep can lead to health problems like heart attacks, diabetes, and even cancer. Since individuals with psoriasis have these same health problems, getting better sleep may help to keep them happier and healthier. This study will look at how individuals with psoriasis sleep and if their sleep is different than indivuduals without psoriasis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with a diagnosis of moderate to severe plaque type psoriasis confirmed by the principal investigator. Moderate to severe psoriasis will be defined as affected BSA ≥3%. Healthy controls will be age and sex matched (see below) subjects with no prior or current history of psoriasis.
✓. Are at least 18 years of age
✓. Psoriasis has been stable over the last 3 months

Exclusion criteria

✕. Subjectively reported poor sleep quality using the Pittsburg Sleep Quality Index (PSQI) (defined as a global score \>5)
✕. Fluent in English
✕. Demonstrate understanding of the study and willingness to participate as evidenced by voluntary informed consent
✕. Patients with guttate, erythrodermic, or pustular psoriasis subtypes
✕. Having a previous diagnosis of obstructive sleep apnea (OSA) or another medically defined sleep disorder or fall into the intermediate or high-risk groups for having OSA as calculated by the STOP-BANG questionnaire
✕. Subjects who have used the following treatments for psoriasis: phototherapy (UVB) in the last 2 weeks, photochemotherapy (PUVA) in the last 4 weeks, oral systemic treatments in the last 4 weeks, biologic immunomodulating agents in the last 12 weeks, or have had exposure to any other investigational drug/device within 30 days prior to study entry
✕. Subjects who have used any over the counter or prescription sleep aids within five half-lives of the agent in question.

What they're measuring

Sleep efficiency

Timeframe: Average over 3 consecutive nights of sleep

Trial details

NCT IDNCT05102474

SponsorUniversity of California, San Francisco

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-07-03

View on ClinicalTrials.gov More Psoriasis Vulgaris trials